CN111467271A - 一种含乙酰化透明质酸的护肤品 - Google Patents
一种含乙酰化透明质酸的护肤品 Download PDFInfo
- Publication number
- CN111467271A CN111467271A CN202010304765.XA CN202010304765A CN111467271A CN 111467271 A CN111467271 A CN 111467271A CN 202010304765 A CN202010304765 A CN 202010304765A CN 111467271 A CN111467271 A CN 111467271A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- skin care
- care product
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 41
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 41
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 41
- 239000000047 product Substances 0.000 claims abstract description 69
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 42
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 42
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000706 filtrate Substances 0.000 claims abstract description 26
- 238000000855 fermentation Methods 0.000 claims abstract description 25
- 230000004151 fermentation Effects 0.000 claims abstract description 25
- 244000068988 Glycine max Species 0.000 claims abstract description 21
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 21
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims abstract description 20
- 241000609666 Tuber aestivum Species 0.000 claims abstract description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 43
- 229960005323 phenoxyethanol Drugs 0.000 claims description 43
- -1 polydimethylsiloxane Polymers 0.000 claims description 32
- 229920001285 xanthan gum Polymers 0.000 claims description 24
- 239000000230 xanthan gum Substances 0.000 claims description 24
- 229940082509 xanthan gum Drugs 0.000 claims description 24
- 235000010493 xanthan gum Nutrition 0.000 claims description 24
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 19
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 claims description 18
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 18
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 18
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 18
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 18
- 108010087806 Carnosine Proteins 0.000 claims description 18
- 229920001202 Inulin Polymers 0.000 claims description 18
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 18
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims description 18
- 229940124277 aminobutyric acid Drugs 0.000 claims description 18
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 18
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 18
- 229940044199 carnosine Drugs 0.000 claims description 18
- 239000004359 castor oil Substances 0.000 claims description 18
- 235000019438 castor oil Nutrition 0.000 claims description 18
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 18
- 229910003472 fullerene Inorganic materials 0.000 claims description 18
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 18
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 18
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 18
- 229940029339 inulin Drugs 0.000 claims description 18
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 18
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 claims description 16
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 claims description 16
- VKIJBOMCWLTQBD-UHFFFAOYSA-N benzoic acid N-(2-hydroxyphenyl)propanamide Chemical compound C(C1=CC=CC=C1)(=O)O.C(CC)(=O)NC1=C(C=CC=C1)O VKIJBOMCWLTQBD-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 229930182478 glucoside Natural products 0.000 claims description 12
- 238000007599 discharging Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 6
- 229940067599 ascorbyl glucoside Drugs 0.000 claims description 6
- 241001522129 Pinellia Species 0.000 claims description 4
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 4
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical compound C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 abstract description 12
- 230000003020 moisturizing effect Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 210000001339 epidermal cell Anatomy 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000008591 skin barrier function Effects 0.000 abstract description 4
- 230000002087 whitening effect Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 238000001704 evaporation Methods 0.000 abstract description 2
- 230000008020 evaporation Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000037384 skin absorption Effects 0.000 abstract description 2
- 231100000274 skin absorption Toxicity 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 240000008570 Digitaria exilis Species 0.000 abstract 1
- 235000005459 Digitaria exilis Nutrition 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 description 1
- 229920008712 Copo Polymers 0.000 description 1
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 description 1
- 241000862632 Soja Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种含乙酰化透明质酸的护肤品,将二裂酵母发酵产物滤液、乙酰化透明质酸钠、野大豆籽提取物以及夏块菌提取物复配,制备得到的护肤品具有修护、抗皱抗衰、保湿抗炎美白等功效。而且本发明护肤品具有高吸肤性,因为乙酰化透明质酸钠具有极好的皮肤亲和性,即使经过冲洗,也可牢牢吸附在肌肤上,发挥持久保湿、柔肤等功效;具有双倍保湿力,能发挥双倍的保湿能力;可短时间内快速结合水分,提高皮肤水分含量,使肌肤持续水润12h。本发明护肤品能够修复皮肤屏障,AcHA不仅能促进表皮细胞增殖,还能修复受损的表皮细胞,增强表皮角质层屏障功能,提高肌肤的自然抵御能力;从而高效减少皮肤内部水分蒸发,改善皮肤粗糙、干燥状态。
Description
技术领域
本发明属于化妆品领域,特别涉及一种含乙酰化透明质酸的护肤品。
背景技术
人体肌肤表层有六大防护屏障,包括渗透屏障、化学物质屏障、刺激屏障、自由基屏障、机械力屏障和免疫屏障。但是生活压力、饮食以及外界环境都有可能造成皮肤屏障受损,减弱肌肤防护屏障。拥有健康的皮肤屏障,能够抵御外界有害物、刺激物和日光的影响,以及拥有保湿及调节作用。如何找到一种使用安全、有效恢复皮肤屏障的产品成为日益严峻的问题。
乙酰化透明质酸从结构上来说,是两种葡萄糖衍生物的缩合,这个结构不断重复,就成了透明质酸,这和大多数多糖的结构也非常接近,也正是这个结构,才有多糖特有的功能—保湿。透明质酸是皮肤中天然保湿因子的一种,具有极其强大的保湿作用。现在许多流行的保湿成分,多数也是皮肤中固有的成分,这样不但听起来更加安全,而且实际上也能补充一些皮肤中失去的东西,而不像传统矿物油那样只是盖在皮肤上,完全不能吸收。另外透明质酸也是人体其他组织中不可缺少的组分,包括眼睛、关节、神经组织等,所以透明质酸一开始用来作为药用成分还是比较普遍的,比如滴眼液等物质。
本发明根据现有问题,力求研制一种含乙酰化透明质酸的护肤品。
发明内容
本发明的目的在于提供一种含乙酰化透明质酸的护肤品。
本发明所采取的技术方案是:
本发明的第一方面,提供了一种含乙酰化透明质酸的护肤品,包含以下组分:
A.苯氧乙醇、透明质酸钠、丙烯酰二甲基牛磺酸铵/VP共聚物、EDTA二钠、黄原胶、乙醇;
B.PEG-20甲基葡糖倍半硬脂酸酯、PEG-60氢化蓖麻油、聚二甲基硅氧烷、辛基十二醇;
C.抗坏血酸葡糖苷;
D.氢氧化钠;
E.二裂酵母发酵产物滤液、棕榈酰四肽-7、肌肽、苯氧乙醇、辛甘醇、菊粉/水/α-葡聚糖寡糖、香精、氨基丁酸、富勒烯、羟苯基丙酰胺苯甲酸、夏块菌提取物、野大豆籽提取物;
F.乙酰化透明质酸钠;
纯化水余量。
根据本发明的实施例,包含以下重量份的组分:
A.苯氧乙醇6~8份、透明质酸钠0.2~0.6份、AVC10~18份、EDTA二钠0.02~0.08份、黄原胶7~12份、乙醇3~7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.1~0.5份、PEG-60氢化蓖麻油0.04~0.1份、聚二甲基硅氧烷1~1.5份、辛基十二醇0.1~0.3份;
C.抗坏血酸葡糖苷0.2~0.5份;
D.氢氧化钠0.01~0.05份;
E.二裂酵母发酵产物滤液7~12份、棕榈酰四肽-7 0.5~1.2份、肌肽0.1~0.4份、苯氧乙醇0.05~0.3份、辛甘醇0.01~0.2份、菊粉/水/α-葡聚糖寡糖0.3~0.7份、香精0.01~0.04份、氨基丁酸0.1~0.4份、富勒烯0.01~0.2份、羟苯基丙酰胺苯甲酸0.1~0.4份、夏块菌提取物0.2~0.7份、野大豆籽提取物1.1~1.9份;
F.乙酰化透明质酸钠0.1~0.4份;
根据本发明的实施例,还包括水。
根据本发明的实施例,包含以下重量份的组分:
A.苯氧乙醇5~7份、透明质酸钠0.2~0.3份、AVC 10~15份、EDTA二钠0.02~0.05份、黄原胶10~12份、乙醇4~7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25~0.35份、PEG-60氢化蓖麻油0.06~0.09份、聚二甲基硅氧烷1.2~1.5份、辛基十二醇0.12~0.22份;
C.抗坏血酸葡糖苷0.2~0.3份;
D.氢氧化钠0.01~0.02份;
E.二裂酵母发酵产物滤液7~10份、棕榈酰四肽-7 0.5~0.8份、肌肽0.1~0.2份、苯氧乙醇0.1~0.3份、辛甘醇0.01~0.05份、菊粉/水/α-葡聚糖寡糖0.3~0.5份、香精0.02~0.04份、氨基丁酸0.2~0.4份、富勒烯0.01~0.05份、羟苯基丙酰胺苯甲酸0.1~0.15份、夏块菌提取物0.5~0.7份、野大豆籽提取物1.1~1.3份;
F.乙酰化透明质酸钠0.1~0.2份。
根据本发明的实施例,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份。
根据本发明的实施例,所述苯氧乙醇为4~6%苯氧乙醇。
根据本发明的实施例,所述AVC为2~3%AVC。
根据本发明的实施例,所述黄原胶为2~3%黄原胶。
根据本发明的实施例,所述二裂酵母发酵产物滤液的制备方法,将二裂酵母进行发酵后,过滤取滤液即为二裂酵母发酵产物滤液。
本发明第二方面,提供了前面任一所述含乙酰化透明质酸的护肤品的制备方法,包括以下步骤:按照任一所述组分进行称取,并分别混合成A、B、C、D、E和F组分,搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
本发明配方的功效:
二裂酵母发酵产物滤液(广州诺然生物科技有限公司),英文名称是BIFIDAFERMENT FILTRATE,在化妆品、护肤品里主要作用是美白祛斑,抗氧化剂,保湿剂,风险系数为,比较安全,可以放心使用。二裂酵母发酵产物滤液为保湿剂、皮肤调理剂。
乙酰化透明质酸钠(AcHA)是由天然保湿因子透明质酸钠(HA)经乙酰化反应得到。乙酰基的引入,使AcHA兼具亲水性和亲脂性,可发挥双倍保湿、修护角质层屏障、提高皮肤弹性等生物活性,从而改善肌肤干燥、粗糙状态,令肌肤柔软有弹力。
野大豆籽提取物,英文名称是GLYCINE SOJA(SOYBEAN)SEED EXTRACT,在化妆品、护肤品里主要作用是抗氧化剂,保湿剂,风险系数为1,比较安全,可以放心使用。从野大豆的籽粒中提取的纯天然产物,含有丰富的黄酮等成分,能够促进纤维芽细胞的生长,具有活肤,抗衰老的作用;同时能保持皮肤的水分,有保湿功效。
夏块菌提取物,能够抑制黑色素细胞中酪氨酸酶活力,抑制黑色素合成,具有美白效果。表1是本发明配方来源。
表1
本发明的有益效果是:
本发明通过特定的配方,将二裂酵母发酵产物滤液、乙酰化透明质酸钠、野大豆籽提取物以及夏块菌提取物进行复配,制备得到的护肤品具有修护、抗皱抗衰、保湿、抗炎、美白等功效。而且本发明护肤品具有高“吸”肤性,因为乙酰化透明质酸钠具有极好的皮肤亲和性,即使经过冲洗,也可牢牢吸附在肌肤上,发挥持久保湿、柔肤等功效。本发明护肤品具有双倍保湿力,能发挥双倍的保湿能力;同时,AcHA可短时间内快速结合水分,提高皮肤水分含量,使肌肤持续水润12h。本发明护肤品能够修复皮肤屏障,AcHA不仅能促进表皮细胞增殖,还能修复受损的表皮细胞,增强表皮角质层屏障功能,提高肌肤的自然抵御能力;从而高效减少皮肤内部水分蒸发,改善皮肤粗糙、干燥状态。
具体实施方式
下面结合实施例对本发明中的技术方案进行清楚、完整的说明,但并不局限于此。
实施例1
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇6份、透明质酸钠0.2份、AVC(丙烯酰二甲基牛磺酸铵/VP共聚物)10份、EDTA二钠0.02份、黄原胶7份、乙醇3份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.1份、PEG-60氢化蓖麻油0.04份、聚二甲基硅氧烷
1份、辛基十二醇0.1份;
C.抗坏血酸葡糖苷0.2份;
D.氢氧化钠0.01份;
E.二裂酵母发酵产物滤液7份、棕榈酰四肽-7 0.5份、肌肽0.1份、苯氧乙醇0.05份、辛甘醇0.01份、菊粉/水/α-葡聚糖寡糖0.3份、香精0.01份、氨基丁酸0.1份、富勒烯0.01份、羟苯基丙酰胺苯甲酸0.1份、夏块菌提取物0.2份、野大豆籽提取物1.1份;
F.乙酰化透明质酸钠0.1份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
实施例2
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇8份、透明质酸钠0.6份、AVC18份、EDTA二钠0.08份、黄原胶12份、乙醇7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.5份、PEG-60氢化蓖麻油0.1份、聚二甲基硅氧烷1.5份、辛基十二醇0.3份;
C.抗坏血酸葡糖苷0.5份;
D.氢氧化钠0.05份;
E.二裂酵母发酵产物滤液12份、棕榈酰四肽-7 1.2份、肌肽0.4份、苯氧乙醇0.3份、辛甘醇0.2份、菊粉/水/α-葡聚糖寡糖0.7份、香精0.04份、氨基丁酸0.4份、富勒烯0.2份、羟苯基丙酰胺苯甲酸0.4份、夏块菌提取物0.7份、野大豆籽提取物1.9份;
F.乙酰化透明质酸钠0.4份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
实施例3
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.2份、AVC 10份、EDTA二钠0.02份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.2份;
D.氢氧化钠0.01份;
E.二裂酵母发酵产物滤液7份、棕榈酰四肽-7 0.5份、肌肽0.1份、苯氧乙醇0.1份、辛甘醇0.01份、菊粉/水/α-葡聚糖寡糖0.3份、香精0.02份、氨基丁酸0.2份、富勒烯0.01份、羟苯基丙酰胺苯甲酸0.1份、夏块菌提取物0.5份、野大豆籽提取物1.1份;
F.乙酰化透明质酸钠0.1份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
实施例4
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇7份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶12份、乙醇7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.35份、PEG-60氢化蓖麻油0.09份、聚二甲基硅氧烷1.5份、辛基十二醇0.22份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.3份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.04份、氨基丁酸0.4份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.7份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
实施例5
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
实施例6
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5.5份、透明质酸钠0.2份、AVC 14份、EDTA二钠0.07份、黄原胶11份、乙醇5份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.3份、PEG-60氢化蓖麻油0.09份、聚二甲基硅氧烷1.5份、辛基十二醇0.22份;
C.抗坏血酸葡糖苷0.4份;
D.氢氧化钠0.03份;
E.二裂酵母发酵产物滤液11份、棕榈酰四肽-7 0.9份、肌肽0.3份、苯氧乙醇0.2份、辛甘醇0.07份、菊粉/水/α-葡聚糖寡糖0.7份、香精0.04份、氨基丁酸0.3份、富勒烯0.06份、羟苯基丙酰胺苯甲酸0.2份、夏块菌提取物0.6份、野大豆籽提取物1.4份;
F.乙酰化透明质酸钠0.3份;
纯化水余量。
制备方法,按照A、B、C、D、E和F组分分别称取、配制,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
对比例1
化妆品组合物,包含以下组分:RTH031黄原胶XANTHAN GUM 2份、RMO009丁二醇BUTYLENE GLYCOL 2份、RMO016丙二醇PROPYLENE GLYCOL 2份、RMO004双丙甘醇DIPROPYLENE GLYCOL 3.4份、RMO015甘油GLYCERIN 2份、RPV013苯氧乙醇PHENOXYETHANOL0.4份、RMO050辛甘醇CAPRYLYL GLYCOL 0.2份、ROT021水
AQUA 88份。
对比例2
化妆品组合物,包含以下组分:RMO009丁二醇BUTYLENE GLYCOL 2份、RMO016丙二醇PROPYLENE GLYCOL 2份、RMO004双丙甘醇DIPROPYLENE GLYCOL 3.4份、RMO015甘油GLYCERIN 2份、RPV013苯氧乙醇PHENOXYETHANOL 0.4份、RMO050辛甘醇CAPRYLYL GLYCOL0.2份。
对比例3
化妆品组合物,包含以下组分:RTH021丙烯酰二甲基牛磺酸铵/VP共聚物AMMONIUMACRYLOYLDIMETHYLTAURATE/VP COPOLYMER 2份、RMO009丁二醇BUTYLENE GLYCOL 2份、RMO016丙二醇PROPYLENE GLYCOL 2份、RMO004双丙甘醇DIPROPYLENE GLYCOL 3.4份、RMO015甘油GLYCERIN 2份、RPV013苯氧乙醇PHENOXYETHANOL 0.4份、RMO050辛甘醇CAPRYLYL GLYCOL 0.2份、ROT022水AQUA 88。
对比例4
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
对比例5
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
对比例6
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
对比例7
含乙酰化透明质酸的护肤品,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份、野大豆籽提取物1.3份;
纯化水余量。
对以上实施例和对比例做进一步效果检测。
测定本发明实施例1和对比例的抗氧活性(AOA),AOA表示滴定100g所分析的物质消耗的库仑量,如表2。
表2
测定皮肤肤色L值,使用德国Courage Khazaka(CK)公司生产的皮肤颜色测试仪Colorimeter CL400,通过测量产品使用前后皮肤L值的变化,评估其对皮肤透亮度的影响,对起始L值平均值相同的三组受试者进行检测,每组10人,周期为4周,结果取平均值,如表3。
表3
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | ||
0周 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | |
4周 | 57.6 | 58.4 | 58.3 | 58.2 | 57.9 | 58.1 | |
对比例1 | 对比例2 | 对比例3 | 对比例4 | 对比例5 | 对比例6 | 对比例7 | |
0周 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 |
4周 | 53.3 | 53.4 | 53.6 | 54.5 | 53.7 | 53.8 | 54.1 |
测定皮肤水合度,使三组受试者的起始平均值相同,每组10人,周期为四周,结果取平均值,如表4。
表4
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | ||
0周 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 | |
4周 | 36.3 | 37.2 | 37.1 | 36.4 | 36.8 | 37.2 | |
对比例1 | 对比例2 | 对比例3 | 对比例4 | 对比例5 | 对比例6 | 对比例7 | |
0周 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 |
4周 | 34.5 | 34.3 | 34.1 | 35.1 | 34.9 | 34.7 | 34.6 |
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种含乙酰化透明质酸的护肤品,其特征在于,包含以下组分:
A.苯氧乙醇、透明质酸钠、丙烯酰二甲基牛磺酸铵/VP共聚物、EDTA二钠、黄原胶、乙醇;
B.PEG-20甲基葡糖倍半硬脂酸酯、PEG-60氢化蓖麻油、聚二甲基硅氧烷、辛基十二醇;
C.抗坏血酸葡糖苷;
D.氢氧化钠;
E.二裂酵母发酵产物滤液、棕榈酰四肽-7、肌肽、苯氧乙醇、辛甘醇、菊粉/水/α-葡聚糖寡糖、香精、氨基丁酸、富勒烯、羟苯基丙酰胺苯甲酸、夏块菌提取物、野大豆籽提取物;
F.乙酰化透明质酸钠。
2.根据权利要求1所述的含乙酰化透明质酸的护肤品,其特征在于,还包括水。
3.根据权利要求1所述的含乙酰化透明质酸的护肤品,其特征在于,包含以下重量份的组分:
A.苯氧乙醇6~8份、透明质酸钠0.2~0.6份、AVC10~18份、EDTA二钠0.02~0.08份、黄原胶7~12份、乙醇3~7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.1~0.5份、PEG-60氢化蓖麻油0.04~0.1份、聚二甲基硅氧烷1~1.5份、辛基十二醇0.1~0.3份;
C.抗坏血酸葡糖苷0.2~0.5份;
D.氢氧化钠0.01~0.05份;
E.二裂酵母发酵产物滤液7~12份、棕榈酰四肽-7 0.5~1.2份、肌肽0.1~0.4份、苯氧乙醇0.05~0.3份、辛甘醇0.01~0.2份、菊粉/水/α-葡聚糖寡糖0.3~0.7份、香精0.01~0.04份、氨基丁酸0.1~0.4份、富勒烯0.01~0.2份、羟苯基丙酰胺苯甲酸0.1~0.4份、夏块菌提取物0.2~0.7份、野大豆籽提取物1.1~1.9份;
F.乙酰化透明质酸钠0.1~0.4份。
4.根据权利要求3所述的含乙酰化透明质酸的护肤品,其特征在于,包含以下重量份的组分:
A.苯氧乙醇5~7份、透明质酸钠0.2~0.3份、AVC 10~15份、EDTA二钠0.02~0.05份、黄原胶10~12份、乙醇4~7份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25~0.35份、PEG-60氢化蓖麻油0.06~0.09份、聚二甲基硅氧烷1.2~1.5份、辛基十二醇0.12~0.22份;
C.抗坏血酸葡糖苷0.2~0.3份;
D.氢氧化钠0.01~0.02份;
E.二裂酵母发酵产物滤液7~10份、棕榈酰四肽-7 0.5~0.8份、肌肽0.1~0.2份、苯氧乙醇0.1~0.3份、辛甘醇0.01~0.05份、菊粉/水/α-葡聚糖寡糖0.3~0.5份、香精0.02~0.04份、氨基丁酸0.2~0.4份、富勒烯0.01~0.05份、羟苯基丙酰胺苯甲酸0.1~0.15份、夏块菌提取物0.5~0.7份、野大豆籽提取物1.1~1.3份;
F.乙酰化透明质酸钠0.1~0.2份;
纯化水余量。
5.根据权利要求4所述的含乙酰化透明质酸的护肤品,其特征在于,包含以下重量份的组分:
A.苯氧乙醇5份、透明质酸钠0.3份、AVC 15份、EDTA二钠0.05份、黄原胶10份、乙醇4份;
B.PEG-20甲基葡糖倍半硬脂酸酯0.25份、PEG-60氢化蓖麻油0.06份、聚二甲基硅氧烷1.2份、辛基十二醇0.12份;
C.抗坏血酸葡糖苷0.3份;
D.氢氧化钠0.02份;
E.二裂酵母发酵产物滤液10份、棕榈酰四肽-7 0.8份、肌肽0.2份、苯氧乙醇0.1份、辛甘醇0.05份、菊粉/水/α-葡聚糖寡糖0.5份、香精0.02份、氨基丁酸0.2份、富勒烯0.05份、羟苯基丙酰胺苯甲酸0.15份、夏块菌提取物0.5份、野大豆籽提取物1.3份;
F.乙酰化透明质酸钠0.2份;
纯化水余量。
6.根据权利要求1~5任一项所述的含乙酰化透明质酸的护肤品,其特征在于,所述苯氧乙醇为4~6%苯氧乙醇。
7.根据权利要求1~5任一项所述的含乙酰化透明质酸的护肤品,其特征在于,所述AVC含量为2~3%。
8.根据权利要求1~5任一项所述的含乙酰化透明质酸的护肤品,其特征在于,所述黄原胶为2~3%黄原胶。
9.根据权利要求1~5任一项所述的含乙酰化透明质酸的护肤品,所述二裂酵母发酵产物滤液的制备方法,其特征在于,将二裂酵母进行发酵后,过滤取滤液即为二裂酵母发酵产物滤液。
10.权利要求1~9任一所述含乙酰化透明质酸的护肤品的制备方法,其特征在于,包括以下步骤:按照任一所述组分进行称取,并分别配成A、B、C、D、E和F组分,再将所有组分搅拌混匀,出料,即可得到含乙酰化透明质酸的护肤品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010304765.XA CN111467271A (zh) | 2020-04-17 | 2020-04-17 | 一种含乙酰化透明质酸的护肤品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010304765.XA CN111467271A (zh) | 2020-04-17 | 2020-04-17 | 一种含乙酰化透明质酸的护肤品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111467271A true CN111467271A (zh) | 2020-07-31 |
Family
ID=71753792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010304765.XA Pending CN111467271A (zh) | 2020-04-17 | 2020-04-17 | 一种含乙酰化透明质酸的护肤品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111467271A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456569A (zh) * | 2021-07-08 | 2021-10-01 | 安婕妤化妆品科技股份有限公司 | 一种皮肤弹性修复补水面膜及其制备方法 |
CN114452245A (zh) * | 2022-02-22 | 2022-05-10 | 北京淡适生物科技有限公司 | 一种透明质酸酵母精华液及其制备方法 |
CN115215948A (zh) * | 2022-06-02 | 2022-10-21 | 润辉生物技术(威海)有限公司 | 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用 |
CN116370347A (zh) * | 2023-03-31 | 2023-07-04 | 华熙生物科技股份有限公司 | 抗炎组合物及其用途 |
-
2020
- 2020-04-17 CN CN202010304765.XA patent/CN111467271A/zh active Pending
Non-Patent Citations (1)
Title |
---|
安婕妤化妆品科技股份有限公司: "ANGLee PROFESSIONAL安婕妤鑽石烯焕颜精华液", 《国产非特殊用途化妆品备案信息服务平台》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456569A (zh) * | 2021-07-08 | 2021-10-01 | 安婕妤化妆品科技股份有限公司 | 一种皮肤弹性修复补水面膜及其制备方法 |
CN114452245A (zh) * | 2022-02-22 | 2022-05-10 | 北京淡适生物科技有限公司 | 一种透明质酸酵母精华液及其制备方法 |
CN115215948A (zh) * | 2022-06-02 | 2022-10-21 | 润辉生物技术(威海)有限公司 | 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用 |
CN115215948B (zh) * | 2022-06-02 | 2023-07-11 | 润辉生物技术(威海)有限公司 | 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用 |
CN116370347A (zh) * | 2023-03-31 | 2023-07-04 | 华熙生物科技股份有限公司 | 抗炎组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111467271A (zh) | 一种含乙酰化透明质酸的护肤品 | |
CN114848541B (zh) | 一种抗衰祛皱组合物及其制备方法和化妆品及其制备方法 | |
CN110638709A (zh) | 一种抗蓝光的多效修护眼霜及其制备方法 | |
CN109453087B (zh) | 美白透肌水及其制备方法和美白化妆品添加剂 | |
CN109172435B (zh) | 一种豆腐霜及其制备方法 | |
KR101663946B1 (ko) | 인삼꽃 흑효모 발효를 통한 진세노사이드 Rg3 강화 및 이를 유효성분으로 함유하는 화장료 조성물 | |
CN113398016A (zh) | 一种皮肤舒缓修护组合物及化妆品组合物 | |
CN110946784A (zh) | 一种具有提升皮肤屏障功能、加强皮肤健康的护肤组合物 | |
CN109330954B (zh) | 美白亮肤水及其制备方法和酪氨酸酶抑制剂 | |
CN115517999B (zh) | 一种抗衰老组合物及其在美容护肤中的应用 | |
KR20140006494A (ko) | 황금 추출물의 붉은덕다리버섯 균사체 발효물을 함유하는 피부 보습용 화장료 조성물 | |
KR101855207B1 (ko) | 흑효모 발효를 통해 비타민 c 함량이 증가된 카카두플럼 추출물을 함유하는 화장료 조성물 | |
CN111557892A (zh) | 含益生元的化妆品组合物 | |
KR101645476B1 (ko) | 흑효모 발효를 통해 비타민 c 함량이 증가된 산자나무 발효 추출물을 함유하는 화장료 조성물 | |
CN113384497B (zh) | 一种双重保湿修复和改善皮肤弹性的组合物及化妆品 | |
CN114533618A (zh) | 一种美白修复组合物及其制备方法和应用 | |
CN112773761B (zh) | 一种化妆品组合物、精华液及其制备方法 | |
CN114272184A (zh) | 一种多肽组合物,包含其的抗衰老修护眼霜及其制备方法 | |
CN111658587A (zh) | 胶原酶抑制剂组合物、抗衰水分露及其制备方法 | |
CN116637042A (zh) | 一种祛皱抗衰护肤品及其制备方法和应用 | |
KR101587077B1 (ko) | 피부 생리활성을 가지는 백년초 발효물을 포함하는 조성물 | |
CN115025028B (zh) | 一种具有抗蓝光功效的护肤组合物及制备方法、应用 | |
CN113876626B (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
CN114159333B (zh) | 一种肌底液及其制备方法 | |
KR101843976B1 (ko) | 흑효모 발효 발아녹두 추출물을 유효성분으로 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |
|
RJ01 | Rejection of invention patent application after publication |